Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity.
2020-08-06
Used in this study: B-hCD47 mice. Part Author's Institute: Innovent Biologics (Suzhou) Co., Ltd.
More>>